I knew it was going to be one of those days the moment I opened my inbox before sunrise: three portal messages about “the Wegovy pill,” two refill requests marked urgent, one patient asking if they should “double the dose to speed things up,” and another asking — almost apologetically — if the vial they bought online was “basically the same thing.”
By the time I walked into clinic, I’d already seen the entire GLP‑1 era in miniature: hope, scarcity, urgency, confusion, and a quiet thread of shame running through it all.
A few hours later, between rooms, a patient caught me in the hallway. Not dramatic. Not angry. Just tired. The kind of tired you can’t fix with sleep.
“Doc … is this finally the thing that works? Or is it just another trap?”
That question has become the soundtrack of modern metabolic medicine. And with oral Wegovy entering the mainstream, it’s getting louder — because pills travel farther than injections. They slip more easily into routines, into family conversations, into group chats, into the social media narratives that medicine doesn’t always survive intact.
I prescribe GLP‑1 therapies. I also live in the downstream consequences of how we talk about them.
The Miracle I Don’t Want to Minimize
Let me say this clearly: for some patients, GLP‑1 therapy is life-changing.
I’ve watched patients who have tried everything — years of dieting, tracking, bargaining, shame — finally experience what they call “quiet.” Quiet cravings. Quiet food noise. Quiet compulsion.
One patient told me, “It’s like someone turned down the volume in my head.” Another said, “For the first time, I’m not negotiating with myself all day.”
That matters. Not just for weight. For dignity.
When it works well, it doesn’t feel like a shortcut. It feels like biology cooperating. Patients make choices that used to feel impossible, not because their character suddenly improved, but because their physiology finally gave them space. I’ve seen improved blood sugar, better mobility, lower blood pressure, and less inflammation. I’ve watched patients re-enter their lives: travel again, exercise again, stop avoiding photos, stop avoiding mirrors, stop avoiding the doctor.
Hope returns. And that’s powerful medicine.
But hope, unmanaged, can become hazardous.
The Mess That Follows Hype
The public sees the highlight reel. I see what spills into the margins.
I see the patient who can’t tolerate the medication but is terrified to say so because they’re afraid I’ll take it away. They whisper, “I’m miserable,” the way people confess a failure. They’re nauseated, constipated, refluxed, exhausted — and yet they’re losing weight. Their labs look better. The scale is trending down. On paper, it’s a success story.
In the body, it can be suffering.
I see the patient who under-eats to “maximize” loss and then wonders why they’re weak, dizzy, and cold all the time. I see the patient who stops lifting weights because nausea makes movement feel like punishment — and then they lose muscle along with fat. I see the patient who ignores constipation until it becomes a crisis, then ends up in urgent care, then vows never to touch the medication again.
I also see a quieter harm: disappointment.
Patients are told — directly or indirectly — that this should be effortless. But physiology is rarely effortless. When weight loss isn’t linear, when the plateau arrives, or when they regain after stopping, many interpret it as personal failure. They don’t realize discontinuation can unleash predictable rebound appetite signaling. They blame themselves instead of understanding biology.
If we’re honest, sometimes we fail to prepare them for that reality.
Why a Pill Changes the Psychology
A pill isn’t just a new formulation. It’s a new narrative.
Pills feel familiar. Casual. Low-commitment. A daily tablet can feel like something you can start and stop like a supplement — especially when the culture around it frames GLP‑1s as a fast track, a “hack,” or a cosmetic tool rather than chronic disease management.
But GLP‑1 therapy is not casual medicine.
It’s powerful physiology. And the more familiar the delivery feels, the more likely patients are to misinterpret the relationship: titrate quickly, chase speed, ignore side effects, stop abruptly, restart chaotically, or source questionable products because access feels uncertain.
That’s how an effective medication becomes unsafe — not because the molecule changed, but because behavior did.
The Moment I Changed How I Prescribe
A turning point for me came when a patient who was doing “amazing” on paper — weight down, numbers improving — looked at me and said:
“I’m scared to tell you this, but I’m miserable. I can’t eat, I’m constipated, and I’m exhausted. But I can’t stop because I’m finally losing.”
That sentence is the clinical reality of GLP‑1s right now: outcomes and suffering can coexist. If we only track outcomes, we miss the patient.
Since then, I’ve become far more deliberate. I don’t prescribe a GLP‑1 without prescribing a plan.
Not a vague suggestion. A plan.
The Plan I Wish Every Physician Normalized
- Start low, go slow — then go slower.
- If side effects are impairing function, we pause dose escalation. We don’t “win” weight loss by losing the patient.
- Prevent constipation like it matters — because it does.
- Hydration, bowel routine, early interventions, and proactive check-ins. Constipation is a common off-ramp; prevention is easier than rescue.
- Protect lean mass on purpose.
- Protein targets and resistance training are not lifestyle “extras.” They’re part of the prescription. I tell patients: we’re not just shrinking you — we’re strengthening you.
- Define red flags in plain language.
- Severe abdominal pain, persistent vomiting, dehydration, gallbladder-type symptoms, and sudden visual changes are not “normal.” Those are call-now symptoms. Patients shouldn’t have to guess whether they’re being “dramatic.”
- Talk about duration without moralizing it.
- Some patients will need longer-term therapy. Some will taper off successfully. But nobody should be blindsided by rebound biology, and nobody should feel shame for needing a chronic-disease tool for a chronic disease.
What I Tell Patients in One Sentence
“If we use this medication, we’re not chasing a number — we’re building a system you can live in.”
That sentence forces the conversation away from the scale and toward function: strength, sleep, labs, mood, energy, mobility, and sustainability. It also gives me a framework to remove shame from the room.
Because shame makes patients hide side effects. Shame makes them buy mystery medication. Shame makes them stop abruptly without guidance. Shame turns medicine into secrecy.
And secrecy is where people get hurt.
The Real Question Beneath the GLP‑1 Conversation
The hallway question — “Is this finally the thing that works, or another trap?” — isn’t ultimately about pills versus pens.
It’s about trust.
- Trust that we’ll tell the whole truth, not just the celebratory part.
- Trust that we’ll take suffering seriously, even when the numbers look good.
- Trust that we’ll treat obesity like the chronic, relapsing condition it often is — not like a character flaw.
- Trust that we’ll stay with our patients through the miracle and the mess.
Oral Wegovy will expand access. It will also expand noise. For those of us practicing medicine in the middle of it, the takeaway isn’t “prescribe more” or “prescribe less.”
It’s prescribe with a plan, counsel like it matters, and monitor like the stakes are real — because they are.
Shiv Kumar Goel, MD, is a board-certified physician specializing in internal, functional, and aesthetic medicine and the founder of Prime Vitality Wellness in San Antonio, Texas. He writes and speaks on metabolic health, longevity, and the intersection of evidence-based medicine, behavior change, and modern health technology. Learn more at drshivgoel.com.
This article is part of the Medical Insights vertical on Op-Med, which features study breakdowns, resources, and insights from Doximity members on popular topics in medicine. Want to submit to Medical Insights? See our submission guidelines here; note that we are especially interested in articles covering oncology, dermatology, or rheumatology.
Image by Shutterstock
